Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, sold 10,290 shares worth approximately $608,000 on May 18, 2026, at a weighted average price of $59.07 per share. The sale was part of a pre-arranged Rule 10b5-1 trading plan and should not concern investors, as it was non-discretionary. The transaction came after the stock surged 457.71% over one year, driven by encouraging clinical trial data and a $700 million public offering announced in April.